Hit a Plateau on Your GLP-1? Here's What's Actually Going On

Somewhere between month six and month eighteen, it happens to nearly everyone: the scale stops moving. The medication hasn’t changed, you haven’t changed, but the weekly losses that felt automatic have flattened into a line. Cue the anxious search: is my GLP-1 not working anymore?

Short answer: it’s still working. Here’s what a plateau actually is, and what’s worth doing about it.

Plateaus are in the trial data

Look at the weight curves from any major GLP-1 trial and you’ll see the same shape: steep loss in the first months, gradual flattening, then a stable plateau, around week 60 for semaglutide in STEP 1 and a bit later at higher tirzepatide doses in SURMOUNT-1. The plateau isn’t a failure state the trials hid. It’s the expected endpoint of treatment, visible in every published graph.

Why it happens: as you lose weight, your energy needs drop (a smaller body burns fewer calories) while the drug’s appetite suppression stays constant rather than deepening. Eventually intake and expenditure meet, and weight stabilizes. The medication is still suppressing appetite at that point; without it, you wouldn’t hold the plateau, you’d regain.

So the first reframe: a plateau means the drug found your new equilibrium, not that it stopped working.

The questions worth asking at a plateau

Are you at your maintenance dose, or did you stall on the way up? Plateauing at a mid-tier dose is a different situation from plateauing at maximum. If side effects parked you at a lower dose months ago, revisiting the escalation with your prescriber is the most obvious lever. Our side-effects guide covers strategies that make higher doses tolerable.

Has intake quietly crept up? Appetite suppression fades slightly for some people over time, and “food noise” learns workarounds: grazing, liquid calories, the 10 pm cheese raid. A genuinely honest week of tracking answers this faster than speculation. No judgment; the drug reduces hunger, not habit.

Is it actually a plateau, or is it recomposition? If you’ve been lifting and hitting protein targets, which you should be, a stable scale can hide fat loss offset by muscle gain. Waist measurements and progress photos settle it. This is the good kind of plateau; don’t fix it.

How long has it really been? Two flat weeks is noise: water, glycogen, hormones, sodium. A plateau worth acting on is six-plus weeks of no trend with honest adherence.

The levers, ranked by evidence

1. Dose optimization with your prescriber. If you’re below maximum tolerated dose, this is the biggest lever available.
2. Switching medications. Plateaued at max semaglutide? The head-to-head data shows tirzepatide produces further loss on average, and switching after plateau is now routine practice.
3. Recount the calories. Not to crash-diet, just to close the drift. A 200-calorie daily creep fully explains a stall.
4. Add or upgrade resistance training. More muscle raises resting expenditure and improves the composition of any further loss. Cardio helps health and the deficit; lifting defends the engine.
5. Sleep and alcohol audit. Short sleep measurably increases hunger and snacking; alcohol adds calories the drug doesn’t defend against. Boring, effective.

And sometimes: the plateau is the destination

Average loss on these medications is 15–21%, not 40%. If you’ve lost 18% of your starting weight, your labs have improved, and you’re stronger than when you started, then the honest read is that treatment succeeded and you’re in maintenance now. Maintenance isn’t a consolation prize; holding a large weight loss is the thing decades of diet research could rarely achieve at all.

The goal was never a number that keeps falling forever. It was a healthier equilibrium you can actually keep. If that’s where you are, the plateau isn’t your problem. It’s your result.

This article is for general education, not medical advice. Dose changes and medication switches are decisions for you and your prescriber.